International Clinical Trial: Study Comparing Fostrox + Lenvatinib vs. Lenvatinib in Patients with Locally Advanced or Unresectable Advanced Hepatocellular Carcinoma (HCC) who have Received First-line

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (KCT0011819) titled 'Study Comparing Fostrox + Lenvatinib vs. Lenvatinib in Patients with Locally Advanced or Unresectable Advanced Hepatocellular Carcinoma (HCC) who have Received First-line' on April 6.

Study Type: Interventional Study

Study Design: Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT

Primary Sponsor: Bundang CHA General Hospital

Condition:

Neoplasms

Intervention: Drug : - experimental arm: Fostrox30mg, QD, PO(5 days on, 16 days off) + Lenvatinib12mg(=60kg) or 8mg(400 ng/mL

Fostrox (30 mg) will be administered orally once daily (QD) from Days 1 to Day 5 in each 2...